Winship Cancer Institute of Emory University | Strategic Alliance Partners

November 23, 2020

Sagar Lonial MD, FACP, discusses unanswered questions with T-cell engagers in myeloma.

November 17, 2020

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.

November 12, 2020

In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.

November 12, 2020

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

October 16, 2020

Data from a subgroup analysis of the phase 2 GRIFFIN study demonstrated that adding daratumumab to lenalidomide, bortezomib, and dexamethasone improved depth of response, stringent complete response, and minimal residual disease negativity, in Black patients with newly diagnosed multiple myeloma.

October 06, 2020

Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.

September 24, 2020

Sagar Lonial, MD, FACP, discusses the approval of belantamab mafodotin-blmf and how it addressed an unmet need in relapsed/refractory multiple myeloma.

August 24, 2020

Nabil F. Saba, MD, FACP, discusses ​scheduling challenges with cisplatin in head and neck cancer.

August 19, 2020

Nabil F. Saba, MD, FACP, discusses ​emerging sequencing ​strategies in head and neck cancer. 

August 06, 2020

Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

June 24, 2020

Nabil F. Saba, MD, FACP, discusses the future of treatment in head and neck cancer.

June 03, 2020

Sagar Lonial, MD, FACP, discusses the benefits of early intervention in high-risk smoldering multiple myeloma.

May 04, 2020

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses the impact of the coronavirus disease 2019 (COVID-19) on telehealth in head and neck cancer.

April 30, 2020

Nabil F. Saba, MD, FACP, discusses how the COVID-19 pandemic has impacted treatment in head and neck cancer and the health care system at large.

April 29, 2020

Ragini R. Kudchadkar, MD, discusses the biological differences between ocular melanoma and cutaneous melanoma.

April 13, 2020

Obese men with nonmetastatic prostate cancer have higher cardiovascular disease–related mortality and all-cause mortality, and potentially increased prostate cancer–specific mortality.

April 11, 2020

Ragini Kudchadkar, MD, discusses the prognosis of patients with metastatic ocular melanoma and the work being done to define novel approaches in melanoma.

March 31, 2020

Walter J. Curran, Jr, MD, FACR, FASCO, explains the eligibility criteria for immunotherapy and radiation in patients with lung cancer.

March 28, 2020

Sagar Lonial, MD, FACP, discusses the role of targeted therapy in acute myeloid leukemia and acute lymphoblastic leukemia.

March 24, 2020

Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.